EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
暂无分享,去创建一个
H. Tilg | A. Canbay | G. Frühbeck | A. Gastaldelli | H. Yki-Järvinen | V. Ratziu | V. Nobili | L. Mathus-vliegen
[1] J. Reinus,et al. Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. , 2016, Clinics in liver disease.
[2] Rachel M. Brown,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.
[3] Marco Maggioni,et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.
[4] S. Friedman,et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.
[5] F. Pattou,et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.
[6] Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.
[7] M. Carstensen,et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. , 2015, Cell metabolism.
[8] E. Bugianesi,et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[9] A. Burt,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.
[10] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[11] Z. Goodman,et al. Current efforts and trends in the treatment of NASH. , 2015, Journal of hepatology.
[12] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] S. Friedman,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.
[14] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[15] D. Brenner,et al. Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.
[16] N. Lundbom,et al. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. , 2015, The Journal of clinical endocrinology and metabolism.
[17] J. Borén,et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease , 2015, Hepatology.
[18] S. Burks,et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. , 2015, Journal of hepatology.
[19] G. Marchesini,et al. NAFLD incidence and remission: only a matter of weight gain and weight loss? , 2015, Journal of hepatology.
[20] B. Neuschwander‐Tetri,et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] F. Nascimbeni,et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.
[22] H. Yki-Järvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.
[23] F. Pattou,et al. Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study , 2014, Annals of surgery.
[24] J. Lavine,et al. Review article: the management of paediatric nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.
[25] J. Jónasson,et al. Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease , 2014, BMC Gastroenterology.
[26] G. Frühbeck,et al. Increased Cardiometabolic Risk Factors and Inflammation in Adipose Tissue in Obese Subjects Classified as Metabolically Healthy , 2014, Diabetes Care.
[27] O. Cummings,et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. , 2014, Gastroenterology.
[28] E. Gaudio,et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. , 2014, World journal of gastroenterology.
[29] J. Dufour,et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. , 2014, Journal of hepatology.
[30] H. Völzke,et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis , 2014, PLoS medicine.
[31] K. Clément,et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.
[32] Aijaz Ahmed,et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.
[33] Deepak L. Bhatt,et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.
[34] L. N. Valenti,et al. A 4-Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease , 2014, Journal of pediatric gastroenterology and nutrition.
[35] G. Cho,et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population , 2014, Heart.
[36] S. Saab,et al. Impact of coffee on liver diseases: a systematic review , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[37] L. N. Valenti,et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. , 2014, World journal of gastroenterology.
[38] Xiaofei Wang,et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[39] Lawrence A Leiter,et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials , 2014, European Journal of Clinical Nutrition.
[40] J. George,et al. The role of diet and nutritional intervention for the management of patients with NAFLD. , 2014, Clinics in liver disease.
[41] M. Ngu,et al. Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments , 2014, Alimentary pharmacology & therapeutics.
[42] G. Marchesini,et al. The role of medications for the management of patients with NAFLD. , 2014, Clinics in liver disease.
[43] L. Henry,et al. Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets , 2014, Alimentary pharmacology & therapeutics.
[44] H. Conjeevaram,et al. Effect of lifetime alcohol consumption on the histological severity of non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[45] K. Cusi,et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. , 2014, Journal of hepatology.
[46] M. Cole,et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. , 2014, Journal of hepatology.
[47] M. Honda,et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial , 2014, Diabetologia.
[48] M. Al-mallah,et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.
[49] Federico Schena,et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial) , 2013, Hepatology.
[50] P. Bedossa,et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.
[51] S. Mudaliar,et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.
[52] J. Tomlinson,et al. Non-alcoholic fatty liver disease in common endocrine disorders. , 2013, European journal of endocrinology.
[53] B. Neuschwander‐Tetri,et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis , 2013, Alimentary pharmacology & therapeutics.
[54] G. Ward,et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. , 2013, Journal of hepatology.
[55] A. Burt,et al. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? , 2013, European journal of gastroenterology & hepatology.
[56] G. Svegliati-Baroni,et al. A 360-degree overview of paediatric NAFLD: recent insights. , 2013, Journal of hepatology.
[57] G. Targher,et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.
[58] H. Cortez‐Pinto,et al. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. , 2013, Journal of hepatology.
[59] R. DeFronzo,et al. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.
[60] T. Therneau,et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.
[61] D. Torres,et al. Physical activity: an essential component of lifestyle modification in NAFLD , 2012, Nature Reviews Gastroenterology &Hepatology.
[62] V. Wong,et al. Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.
[63] F. Negro,et al. Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States , 2012, Medicine.
[64] L. Gerber,et al. Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study , 2012, Alimentary pharmacology & therapeutics.
[65] M. Abraham,et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.
[66] Sung-il Cho,et al. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men , 2012, International Journal of Obesity.
[67] A. Sanyal,et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). , 2012, Journal of hepatology.
[68] A. Kahraman,et al. Liver Transplantation in Nonalcoholic Steatohepatitis Is Associated with High Mortality and Post-Transplant Complications: A Single-Center Experience , 2012, Digestion.
[69] N. Johnson,et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.
[70] N. Chalasani,et al. What Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use? , 2012, The American Journal of Gastroenterology.
[71] K. Watson,et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study , 2012, The Lancet.
[72] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[73] Christopher D Byrne,et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? , 2012, European heart journal.
[74] P. Vajro,et al. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee , 2012, Journal of pediatric gastroenterology and nutrition.
[75] Zhi‐Jie Zheng,et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.
[76] D. Samuel,et al. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. , 2012, Journal of hepatology.
[77] Catriona A. Burdon,et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.
[78] Kwok-Kin Wong,et al. Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis , 2012, Cancer Prevention Research.
[79] J. Hardies,et al. Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Diabetes Care.
[80] G. Frühbeck,et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity , 2012, International Journal of Obesity.
[81] D. Kleiner,et al. Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research , 2012, Seminars in Liver Disease.
[82] C. Lawton,et al. Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .
[83] Christian Thoma,et al. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.
[84] K. Clément,et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. , 2012, Journal of hepatology.
[85] A. Feldstein,et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.
[86] J. Heimbach,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.
[87] Shira Zelber-Sagi,et al. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. , 2011, World journal of gastroenterology.
[88] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[89] Paolo Crosignani,et al. Fatty liver index and mortality: The cremona study in the 15th year of follow‐up , 2011, Hepatology.
[90] P. Rosenthal,et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.
[91] B. Neuschwander‐Tetri,et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.
[92] Christophe Tzourio,et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.
[93] A. Alisi,et al. I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.
[94] Enzo Bonora,et al. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.
[95] N. Sattar,et al. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data , 2010, Hepatology.
[96] Chris Day,et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.
[97] T. Berg,et al. High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.
[98] D. Reboussin,et al. Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.
[99] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[100] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[101] E. Bugianesi,et al. Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.
[102] V. de Lédinghen,et al. Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.
[103] P. Giral,et al. Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.
[104] Julien Vergniol,et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.
[105] E. Jackvony,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.
[106] J. Newton,et al. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. , 2010, Journal of hepatology.
[107] M. Raponi,et al. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. , 2009, World journal of gastroenterology.
[108] J. Benson,et al. The natural history of non-alcoholic fatty liver disease , 2006 .
[109] W. Coyle,et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.
[110] B. Neuschwander‐Tetri,et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.
[111] K. Birkeland,et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.
[112] B. Neuschwander‐Tetri,et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.
[113] M. Simrén. High- or Low-Carbohydrate Diets: Which Is Better for Weight Loss, Insulin Resistance, and Fatty Livers? , 2009 .
[114] G. Aithal,et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.
[115] Philippe Giral,et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.
[116] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[117] I. Guha,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.
[118] A. Hakkarainen,et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. , 2008 .
[119] Amalia Gastaldelli,et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.
[120] L. N. Valenti,et al. Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study , 2007, The American Journal of Gastroenterology.
[121] A. Häkkinen,et al. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.
[122] Christian Gluud,et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.
[123] J. Dufour,et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[124] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[125] A. Alberti,et al. Review article: chronic hepatitis C – natural history and cofactors , 2005, Alimentary pharmacology & therapeutics.
[126] C. Nievergelt,et al. Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.
[127] Mark Fishbein,et al. Hepatic MRI for Fat Quantitation: Its Relationship to Fat Morphology, Diagnosis, and Ultrasound , 2005, Journal of clinical gastroenterology.
[128] G. Bedogni,et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.
[129] P. Giral,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.
[130] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[131] G. Marchesini,et al. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.
[132] K. Petersen,et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.
[133] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[134] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[135] A. Häkkinen,et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.
[136] S. Caldwell,et al. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.
[137] L. Burgart,et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.
[138] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[139] C. Ryan,et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[140] M. Roden,et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.
[141] Erick M Remer,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[142] G. Brandi,et al. Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.
[143] P. Rosenthal,et al. American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.